DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper the market growth to a certain extent in the coming years.

Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.

Viral vectors segment to register the highest growth in the gene therapy market during the forecast period

The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.

North America will continue to dominate the gene therapy market during the forecast period

Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

Key Benefits of Buying the Report:

This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. Also, this report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.4 Currency

1.5 Limitation

1.6 Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Secondary Data

2.3 Primary Data

2.4 Market Size Estimation

2.5 Market Breakdown and Data Triangulation

2.6 Assumptions for the Study

3 Executive Summary

4 Premium Insights

4.1 Gene Therapy Market Overview

4.2 North America: Market, By Vector (2018)

4.3 Geographical Snapshot of the Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Incidence of Cancer and Other Target Diseases

5.2.1.2 Product Approvals

5.2.1.3 Funding for Gene Therapy Research

5.2.2 Opportunities

5.2.2.1 Strong Product Pipeline

5.2.3 Challenges

5.2.3.1 High Cost of Treatments

6 Gene Therapy Market, By Vector

6.1 Introduction

6.2 Non-Viral Vectors

6.3 Viral Vectors

7 Gene Therapy Market, By Indication

7.1 Introduction

7.2 Neurological Diseases

7.3 Cancer

7.4 Hepatological Diseases

7.5 Duchenne Muscular Dystrophy

7.6 Other Indications

8 Gene Therapy Market, By Delivery Method

8.1 Introduction

8.2 In Vivo Gene Therapy

8.3 Ex Vivo Gene Therapy

9 Gene Therapy Market, By Region

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 Rest of the World

10 Competitive Landscape

10.1 Overview

10.2 Market Share Analysis, 2018

10.3 Key Strategies

10.4 Competitive Leadership Mapping (2018)

10.4.1 Visionary Leaders

10.4.2 Innovators

10.4.3 Dynamic Differentiators

10.4.4 Emerging Companies

11 Company Profiles

11.1 Biogen

11.2 Gilead Sciences, Inc.

11.3 Amgen, Inc.

11.4 Novartis AG

11.5 Orchard Therapeutics Plc

11.6 Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)

11.7 Molmed S.P.A.

11.8 Anges, Inc.

11.9 Bluebird Bio, Inc.

11.10 Human Stem Cells Institute (HSCI)

11.11 SIBIONO Genetech Co., Ltd.

11.12 Shanghai Sunway Biotech Co., Ltd

11.13 Uniqure N.V.

11.14 Gensight Biologics S.A.

11.15 Celgene Corporation (A Bristol-Myers Squibb Company)

11.16 Cellectis

11.17 Sangamo Therapeutics

11.18 Mustang Bio

11.19 AGTC (Applied Genetic Technologies Corporation)

11.20 Poseida Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/xhxwrm

Read more:
Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% - ResearchAndMarkets.com -...

Comments are closed.